ABPath Cytopathology common mistakes
ABPath Cytopathology · Understand the traps and how to avoid them.
Assigning a Bethesda category from a single memorable cell or feature (e.g., one cluster of enlarged nuclei) without first committing to an adequacy assessment and a systematic slide-wide screen at low power.
Candidates under time pressure jump to pattern recognition on the first abnormal field they see, and the exam deliberately includes sparse lesions and distracting benign mimics elsewhere on the same slide.
What to do instead
Adopt a fixed order for every case: adequacy (cell count, transformation zone component, obscuring factors), then low-power architecture, then high-power nuclear detail, then reconcile into a category. Practice narrating this order aloud until it is automatic.
Treating ASC-US and LSIL as interchangeable, or defaulting to LSIL whenever any HPV-type change is present, instead of applying the nuclear-to-cytoplasmic ratio and nuclear atypia thresholds that separate the two.
In practice these categories overlap and are managed similarly, so candidates stop rehearsing the morphologic boundary; the exam tests the boundary precisely because management differs.
What to do instead
Build a two-column discriminator table (nuclear enlargement and hyperchromasia with preserved abundant cytoplasm vs. marked NC ratio increase with irregular nuclear contours) and force yourself to justify the chosen category with two named features before moving on.
Missing significant glandular lesions because attention is fixed on squamous abnormalities, particularly undercalling adenocarcinoma in situ or endometrial adenocarcinoma on a Pap test.
Squamous lesions dominate training volume, and glandular lesions on cytology are often subtle (pseudostratified strips, rosettes, subtle nuclear enlargement) and frequently present in patients whose squamous component is normal.
What to do instead
Add a mandatory glandular pass to every case: actively search for hyperchromatic crowded groups, feathering, rosettes, and stripped atypical nuclei, and separately assess whether the background (tumor diathesis, blood, necrosis) suggests invasion.
Reporting high-grade squamous intraepithelial lesion or carcinoma when the preparation is unsatisfactory or the abnormal cells are few, rather than using the unsatisfactory or adequacy qualifier and explaining the limitation.
Candidates fear being marked wrong for a non-diagnostic answer and over-commit; they also underuse the Bethesda convention that a diagnosis can be rendered with a comment on limited adequacy when high-grade cells are unequivocal.
What to do instead
Learn the explicit adequacy rules and the exception for unequivocal high-grade or malignant cells, then practice writing the exact reporting sentence for each scenario so the distinction between 'unsatisfactory' and 'satisfactory but limited' is fixed in memory.
Diagnosing anal cytology using cervical Bethesda thresholds without adjusting for the poorer adequacy yields and different sampling of anal cytology, and without recognizing the significance of keratinizing dysplastic cells in a patient with a visible lesion.
Anal cytology is low-volume in most training programs, so candidates transfer cervical habits wholesale and misapply adequacy criteria or undercall invasive squamous cell carcinoma.
What to do instead
Review anal-specific adequacy expectations and the morphologic clues to invasion (keratinized bizarre cells, necrosis, prominent nucleoli in a background of inflammation), and deliberately practice a small set of anal cases with known outcomes.
Classifying a cytology specimen as negative or atypical when the sample is acellular or contains only nondiagnostic material, instead of calling it nondiagnostic and stating what would be needed.
Candidates equate 'no malignant cells seen' with a negative diagnosis and overlook that a paucicellular aspirate cannot exclude disease; this is especially tempting in cystic lesions.
What to do instead
Before interpreting any non-gynecologic or FNA case, count or estimate cellularity and ask whether the material could plausibly demonstrate the suspected lesion. If not, issue a nondiagnostic report with a recommendation for repeat or ancillary testing.
Overinterpreting reactive or reparative changes as malignancy in FNA and fluid cytology, particularly calling atypical mesothelial or reactive ductal cells 'suspicious for carcinoma' without corroborating features.
FNA material is distorted by aspiration trauma and air-drying, and reactive cells show enlarged nuclei, prominent nucleoli, and mitoses that mimic malignancy; candidates also anchor on the clinical history.
What to do instead
Require at least two independent malignant features (e.g., high NC ratio plus irregular nuclear membrane plus coarse chromatin) plus architectural evidence before escalating, and consciously generate the benign differential for every 'suspicious' call.
Failing to integrate ancillary studies (immunocytochemistry on cell blocks, flow cytometry, special stains) into the final diagnosis, or ordering a panel that cannot resolve the differential because the markers are not lineage-specific in the given context.
Candidates memorize marker lists in isolation and do not practice choosing a minimal panel tailored to a specific differential, so they either skip ancillary work or request a shotgun panel and then misread the result.
What to do instead
For each major differential (e.g., adenocarcinoma vs. mesothelioma, small blue cell tumors, lymphoid vs. carcinoma), write a three-marker minimum panel with expected results and one pitfall per marker, and rehearse applying it to unknown cases.
Answering laboratory management items from personal anecdote or general intuition rather than from regulatory and accreditation requirements (CLIA personnel and proficiency testing rules, validation of new tests, quality indicators).
Trainees get little formal exposure to regulations and assume management questions are 'common sense,' but the exam tests specific documented requirements and defined roles.
What to do instead
Build a one-page reference of the governing requirements for personnel qualifications, test validation, proficiency testing, and quality management, and answer management questions by naming the rule or standard that applies before choosing an option.
Confusing the roles and required actions in the cytology laboratory workflow, such as who may perform rapid on-site evaluation, how discrepant cytology-histology pairs are resolved, or what triggers a mandatory review, and choosing the option that sounds most efficient.
Candidates optimize for workflow efficiency instead of the mandated quality process, and the exam includes distractors that are operationally sensible but noncompliant.
What to do instead
Map each workflow (on-site evaluation, discrepancy resolution, 100% review of prior high-grade abnormalities, workload limits) to its required personnel and documentation, and practice rejecting plausible-but-noncompliant options by identifying the missing required element.